355 related articles for article (PubMed ID: 26337396)
41. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Garrean CP; Zhang Q; Gonsalves N; Hirano I
Am J Gastroenterol; 2008 Jul; 103(7):1631-7. PubMed ID: 18557714
[TBL] [Abstract][Full Text] [Related]
42. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
[TBL] [Abstract][Full Text] [Related]
43. The role of impedance monitoring in patients with extraesophageal symptoms.
Kavitt RT; Yuksel ES; Slaughter JC; Garrett CG; Hagaman D; Higginbotham T; Vaezi MF
Laryngoscope; 2013 Oct; 123(10):2463-8. PubMed ID: 23857711
[TBL] [Abstract][Full Text] [Related]
44. Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy.
Kunsch S; Neesse A; Linhart T; Nell C; Gress TM; Ellenrieder V
Digestion; 2012; 86(4):315-22. PubMed ID: 23128301
[TBL] [Abstract][Full Text] [Related]
45. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
Becker V; Bajbouj M; Waller K; Schmid RM; Meining A
Aliment Pharmacol Ther; 2007 Nov; 26(10):1355-60. PubMed ID: 17900268
[TBL] [Abstract][Full Text] [Related]
46. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.
Stern EK; Carlson DA; Falmagne S; Hoffmann AD; Carns M; Pandolfino JE; Hinchcliff M; Brenner DM
Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 29110377
[TBL] [Abstract][Full Text] [Related]
47. Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease.
Januszewicz W; Hartley J; Waldock W; Roberts G; Alias B; Hobson A; Wernisch L; di Pietro M
United European Gastroenterol J; 2019 Dec; 7(10):1389-1398. PubMed ID: 31807307
[TBL] [Abstract][Full Text] [Related]
48. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
[TBL] [Abstract][Full Text] [Related]
49. Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict PPI response in GERD patients with extra esophageal symptoms.
Ribolsi M; Guarino MPL; Tullio A; Cicala M
Dig Liver Dis; 2020 Feb; 52(2):173-177. PubMed ID: 31623954
[TBL] [Abstract][Full Text] [Related]
50. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.
Zerbib F; Duriez A; Roman S; Capdepont M; Mion F
Gut; 2008 Feb; 57(2):156-60. PubMed ID: 17951358
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
[TBL] [Abstract][Full Text] [Related]
52. Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.
Tack J; Zerbib F; Blondeau K; des Varannes SB; Piessevaux H; Borovicka J; Mion F; Fox M; Bredenoord AJ; Louis H; Dedrie S; Hoppenbrouwers M; Meulemans A; Rykx A; Thielemans L; Ruth M
Neurogastroenterol Motil; 2015 Feb; 27(2):258-68. PubMed ID: 25530111
[TBL] [Abstract][Full Text] [Related]
53. Combined esophageal multichannel intraluminal impedance and pH monitoring (MII -pH) in the diagnostics and treatment of gastroesophageal reflux disease and its complications.
Masiak W; Wallner G; Wallner J; Pedowski T; Solecki M
Pol Przegl Chir; 2011 Sep; 83(9):488-96. PubMed ID: 22166737
[TBL] [Abstract][Full Text] [Related]
54. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
[TBL] [Abstract][Full Text] [Related]
55. Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux disease.
Yamashita H; Ashida K; Fukuchi T; Nagatani Y; Koga H; Senda K; Eguchi T; Ubukata S; Kawaguchi S; Ueda A; Tanaka T; Ohashi R; Ito D
J Smooth Muscle Res; 2012; 48(5-6):125-35. PubMed ID: 23538509
[TBL] [Abstract][Full Text] [Related]
56. Impedance-high resolution manometry analysis of patients with nonerosive reflux disease.
Ribolsi M; Holloway RH; Emerenziani S; Balestrieri P; Cicala M
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):52-7. PubMed ID: 23891920
[TBL] [Abstract][Full Text] [Related]
57. Proton pump inhibitor-refractory gastroesophageal reflux disease: current diagnosis and management.
Frazzoni L; Fuccio L; Frazzoni M
Minerva Gastroenterol Dietol; 2017 Sep; 63(3):249-256. PubMed ID: 28251845
[TBL] [Abstract][Full Text] [Related]
58. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn.
Frazzoni M; Frazzoni L; Tolone S; De Bortoli N; Savarino V; Savarino E
Am J Gastroenterol; 2018 May; 113(5):670-676. PubMed ID: 29681623
[TBL] [Abstract][Full Text] [Related]
59. Cough and gastroesophageal reflux: from the gastroenterologist end.
Pauwels A; Blondeau K; Dupont L; Sifrim D
Pulm Pharmacol Ther; 2009 Apr; 22(2):135-8. PubMed ID: 19063984
[TBL] [Abstract][Full Text] [Related]
60. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease.
Cicala M; Emerenziani S; Guarino MP; Ribolsi M
World J Gastroenterol; 2013 Oct; 19(39):6529-35. PubMed ID: 24151377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
